@article{oai:soar-ir.repo.nii.ac.jp:00010236,
 author = {Wang,  Yeqin and Yamamoto,  Yoshinari and Shigemori,  Suguru and Watanabe,  Takafumi and Oshiro,  Kazushi and Wang,  Xinyu and Wang,  Pengfei and Sato,  Takashi and Yonekura,  Shinichi and Tanaka,  Sachi and Kitazawa,  Haruki and Shimosato,  Takeshi},
 issue = {2},
 journal = {MOLECULAR THERAPY},
 month = {Feb},
 note = {Advance online publication 6 January 2015, Here, we report a simple and low-cost oral oligodeoxynucleotide (ODN) delivery system targeted to the gut Peyer's patches (PPs). This system requires only Dulbecco's modified eagle's medium, calcium chloride, ODNs, and basic laboratory equipment. ODN nanocapsules (ODNcaps) were directly delivered to the PPs through oral administration and were taken up by macrophages in the PPs, where they induced an immune response. Long-term continuous oral dosing with inhibitory/suppressive ODNcaps (iODNcaps, "iSG3caps" in this study) was evaluated using an atopic dermatitis mouse model to visually monitor disease course. Administration of iSG3caps improved skin lesions and decreased epidermal thickness. Underlying this effect is the ability of iSG3 to bind to and prevent phosphorylation of signal transducer and activator of transcription 6, thereby blocking the interleukin-4 signaling cascade mediated by binding of allergens to type 2 helper T cells. The results of our iSG3cap oral delivery experiments suggest that iSG3 may be useful for treating allergic diseases., Article, MOLECULAR THERAPY. 23(2):297-309 (2015)},
 pages = {297--309},
 title = {Inhibitory/Suppressive oligodeoxynucleotide nanocapsules as simple oral delivery devices for preventing atopic dermatitis in mice},
 volume = {23},
 year = {2015}
}